Total Payments
$8,836
2024 Payments
$2,286
Companies
26
Transactions
478
Medicare Patients
995
Medicare Billing
$139,086
Payment Breakdown by Category
Food & Beverage$8,121 (91.9%)
Research$689.37 (7.8%)
Other$20.00 (0.2%)
Education$5.59 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $8,121 | 473 | 91.9% |
| Unspecified | $689.37 | 1 | 7.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $20.00 | 1 | 0.2% |
| Education | $5.59 | 3 | 0.1% |
Payments by Type
General
$8,147
477 transactions
Research
$689.37
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $2,177 | 127 | $0 (2024) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $1,285 | 107 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $811.13 | 48 | $0 (2024) |
| Eli Lilly and Company | $689.37 | 1 | $0 (2019) |
| Celgene Corporation | $590.36 | 49 | $0 (2024) |
| Ardelyx, Inc. | $548.82 | 26 | $0 (2024) |
| Janssen Biotech, Inc. | $494.29 | 21 | $0 (2024) |
| Synergy Pharmaceuticals Inc | $277.39 | 13 | $0 (2018) |
| E.R. Squibb & Sons, L.L.C. | $270.00 | 2 | $0 (2023) |
| IRONWOOD PHARMACEUTICALS, INC | $241.81 | 13 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,286 | 127 | ABBVIE INC. ($752.49) |
| 2023 | $2,297 | 137 | ABBVIE INC. ($731.68) |
| 2022 | $1,504 | 96 | ABBVIE INC. ($485.04) |
| 2021 | $646.91 | 45 | Salix Pharmaceuticals, a division of Bausch Health US, LLC ($270.17) |
| 2020 | $230.92 | 9 | RedHill Biopharma Inc. ($74.44) |
| 2019 | $1,035 | 20 | Eli Lilly and Company ($689.37) |
| 2018 | $477.10 | 27 | Synergy Pharmaceuticals Inc ($252.66) |
| 2017 | $359.81 | 17 | Merck Sharp & Dohme Corporation ($125.00) |
All Payment Transactions
478 individual payment records from CMS Open Payments — Page 1 of 20
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/21/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Food and Beverage | In-kind items and services | $14.71 | General |
| Category: LIVER DISEASE | ||||||
| 12/17/2024 | Ardelyx, Inc. | IBSRELA (Drug) | Food and Beverage | In-kind items and services | $33.36 | General |
| Category: GASTROENTEROLOGY | ||||||
| 12/17/2024 | AIMMUNE THERAPEUTICS, INC. | VOWST (Biological) | Food and Beverage | In-kind items and services | $9.77 | General |
| Category: GI | ||||||
| 12/16/2024 | ABBVIE INC. | CREON (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $20.00 | General |
| Category: ENDOCRINOLOGY | ||||||
| 12/16/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $13.08 | General |
| Category: IMMUNOLOGY | ||||||
| 12/16/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $1.43 | General |
| Category: IMMUNOLOGY | ||||||
| 12/14/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $13.48 | General |
| Category: IMMUNOLOGY | ||||||
| 12/11/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $7.89 | General |
| Category: Gastroenterology | ||||||
| 11/27/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Food and Beverage | In-kind items and services | $13.51 | General |
| Category: LIVER DISEASE | ||||||
| 11/25/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $22.46 | General |
| Category: IMMUNOLOGY | ||||||
| 11/23/2024 | ABBVIE INC. | SKYRIZI (Biological), RINVOQ | Food and Beverage | In-kind items and services | $17.16 | General |
| Category: IMMUNOLOGY | ||||||
| 11/23/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $16.14 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 11/15/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $22.88 | General |
| Category: INTERNAL MEDICINE | ||||||
| 11/13/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $8.11 | General |
| Category: Gastroenterology | ||||||
| 11/12/2024 | Ardelyx, Inc. | IBSRELA (Drug) | Food and Beverage | In-kind items and services | $28.15 | General |
| Category: GASTROENTEROLOGY | ||||||
| 11/11/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $21.63 | General |
| Category: INTERNAL MEDICINE | ||||||
| 11/08/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $18.48 | General |
| Category: IMMUNOLOGY | ||||||
| 11/06/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | TRULANCE (Drug) | Food and Beverage | In-kind items and services | $10.50 | General |
| Category: Gastroenterology | ||||||
| 11/06/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | TRULANCE (Drug) | Food and Beverage | In-kind items and services | $0.69 | General |
| Category: Gastroenterology | ||||||
| 11/05/2024 | ABBVIE INC. | CREON (Drug) | Food and Beverage | In-kind items and services | $10.69 | General |
| Category: ENDOCRINOLOGY | ||||||
| 11/05/2024 | ABBVIE INC. | CREON (Drug) | Food and Beverage | In-kind items and services | $6.60 | General |
| Category: ENDOCRINOLOGY | ||||||
| 10/30/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Food and Beverage | In-kind items and services | $17.39 | General |
| Category: LIVER DISEASE | ||||||
| 10/28/2024 | AIMMUNE THERAPEUTICS, INC. | VOWST (Biological) | Food and Beverage | In-kind items and services | $8.86 | General |
| Category: GI | ||||||
| 10/25/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Food and Beverage | In-kind items and services | $21.76 | General |
| Category: LIVER DISEASE | ||||||
| 10/25/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $19.73 | General |
| Category: INTERNAL MEDICINE | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL, PLACEBO-CONTROLLED INDUCTION STUDY OF MIRIKIZUMAB IN CONVENTIONAL-FAILED AND BIOLOGIC-FAILED PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (LUCENT 1) | Eli Lilly and Company | $689.37 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 301 | 399 | $252,231 | $39,060 |
| 2022 | 7 | 303 | 410 | $234,859 | $41,911 |
| 2021 | 6 | 223 | 355 | $210,572 | $38,330 |
| 2020 | 4 | 168 | 274 | $113,480 | $19,784 |
Total Patients
995
Total Services
1,438
Medicare Billing
$139,086
Procedure Codes
23
All Medicare Procedures & Services
23 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 92 | 143 | $81,037 | $16,074 | 19.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 90 | 136 | $31,704 | $10,188 | 32.1% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 40 | 40 | $49,640 | $3,432 | 6.9% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2023 | 30 | 30 | $50,670 | $3,407 | 6.7% |
| 45378 | Diagnostic exam of large bowel using a flexible endoscope | Facility | 2023 | 19 | 20 | $28,320 | $3,171 | 11.2% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 30 | 30 | $10,860 | $2,788 | 25.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 111 | 200 | $48,400 | $16,282 | 33.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 42 | 60 | $36,000 | $7,074 | 19.7% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 64 | 64 | $23,168 | $6,385 | 27.6% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2022 | 31 | 31 | $52,359 | $4,265 | 8.1% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 33 | 33 | $40,953 | $3,594 | 8.8% |
| 45384 | Removal of polyps or growths of large bowel using a flexible endoscope with electrical cautery | Facility | 2022 | 11 | 11 | $18,403 | $2,363 | 12.8% |
| 45378 | Diagnostic exam of large bowel using a flexible endoscope | Facility | 2022 | 11 | 11 | $15,576 | $1,948 | 12.5% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 87 | 216 | $52,539 | $18,339 | 34.9% |
| 45380 | Biopsy of the large bowel using an endoscope (colonoscopy) | Facility | 2021 | 29 | 31 | $52,359 | $5,840 | 11.2% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Office | 2021 | 44 | 44 | $15,928 | $4,712 | 29.6% |
| 43239 | Biopsy of the esophagus, stomach, and/or upper small bowel using an endoscope | Facility | 2021 | 38 | 38 | $47,158 | $3,980 | 8.4% |
| 45385 | Removal of polyps or growths in large bowel using an endoscope (colonoscopy) using a mechanical snare | Facility | 2021 | 12 | 12 | $22,764 | $2,914 | 12.8% |
| 45378 | Diagnostic examination of the colon (large bowel) using an endoscope(colonoscopy); high risk | Facility | 2021 | 13 | 14 | $19,824 | $2,546 | 12.8% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 94 | 200 | $47,849 | $12,393 | 25.9% |
| 43239 | Biopsy of the esophagus, stomach, and/or upper small bowel using an endoscope | Facility | 2020 | 31 | 31 | $38,471 | $3,114 | 8.1% |
| 99203 | New patient office or other outpatient visit, typically 30 minutes | Office | 2020 | 32 | 32 | $11,584 | $2,320 | 20.0% |
| 45378 | Diagnostic examination of large bowel using an endoscope | Facility | 2020 | 11 | 11 | $15,576 | $1,957 | 12.6% |
About Dr. Jonathan Rieber, MD
Dr. Jonathan Rieber, MD is a Gastroenterology healthcare provider based in New York, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/14/2005. The National Provider Identifier (NPI) number assigned to this provider is 1023093721.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jonathan Rieber, MD has received a total of $8,836 in payments from pharmaceutical and medical device companies, with $2,286 received in 2024. These payments were reported across 478 transactions from 26 companies. The most common payment nature is "Food and Beverage" ($8,121).
As a Medicare-enrolled provider, Rieber has provided services to 995 Medicare beneficiaries, totaling 1,438 services with total Medicare billing of $139,086. Data is available for 4 years (2020–2023), covering 23 distinct procedure/service records.
Ad
Practice Information
- Specialty Gastroenterology
- Location New York, NY
- Active Since 12/14/2005
- Last Updated 06/06/2014
- Taxonomy Code 207RG0100X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1023093721
Products in Payments
- XIFAXAN (Drug) $863.54
- ZEPOSIA (Drug) $832.05
- RINVOQ (Biological) $818.54
- ENTYVIO (Biological) $747.07
- LINZESS (Drug) $578.15
- IBSRELA (Drug) $548.82
- STELARA (Biological) $494.29
- TRULANCE (Drug) $401.66
- SKYRIZI (Biological) $389.35
- Trulance (Drug) $277.39
- ZENPEP (Drug) $241.00
- CREON (Drug) $236.86
- Linzess (Drug) $201.26
- HUMIRA (Biological) $155.92
- ZEPATIER (Drug) $125.00
- VIBERZI (Drug) $120.30
- Talicia (Drug) $87.92
- DUPIXENT (Biological) $80.38
- Amitiza (Drug) $77.86
- VOWST (Biological) $76.80
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Gastroenterology Doctors in New York
Arthur Kornbluth, Md, MD
Gastroenterology — Payments: $2.4M
Gastroenterology $2.4M
Dr. David Carr-Locke, Md Frcp Facg Masge, MD FRCP FACG MASGE
Gastroenterology — Payments: $2.3M
Gastroenterology $2.3M
Jean-Frederic Colombel, M.d, M.D
Gastroenterology — Payments: $1.1M
Gastroenterology $1.1M
Dr. Bruce Sands, Md, MD
Gastroenterology — Payments: $1.0M
Gastroenterology $1.0M
Ellen Scherl, Md, MD
Gastroenterology — Payments: $880,329
Gastroenterology $880,329
Sonal Kumar, Md, MD
Gastroenterology — Payments: $769,554
Gastroenterology $769,554